𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pharmacokinetics of oral diltiazem and five of its metabolites in patients with chronic renal failure

✍ Scribed by Maha Tawashi; Julien Marc-aurèle; Daniel Bichet; Jean Spénard; Lyne Larivière; Daniel Plante; Gilles Caillé

Publisher
John Wiley and Sons
Year
1991
Tongue
English
Weight
422 KB
Volume
12
Category
Article
ISSN
0142-2782

No coin nor oath required. For personal study only.

✦ Synopsis

The pharmacokinetics of oral diltiazem were studied in 10 patients with chronic renal failure not requiring dialysis and in five healthy volunteers after a single dose of 120mg. We found that patients with chronic renal failure had lower amounts of unchanged diltiazem and of its main metabolite (MA) in urine and a trend to have slightly higher values of plasma concentration. Since the terminal elimination phase is not affected by chronic renal failure we conclude that this trend is probably the result of alterations in the volume of distribution of diltiazem in these patients.

📜 SIMILAR VOLUMES

Pharmacokinetics of intravenous diltiaze
Pharmacokinetics of intravenous diltiazem and five of its metabolites in patients with chronic renal failure and in healthy volunteers
✍ Maha Tawashi; Julien Marc-aurèle; Daniel Bichet; Jean Spénard; Lyne Larivière; D 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 330 KB 👁 2 views

The pharmacokinetics of diltiazem were studied in seven patients with chronic renal failure (CRF) not requiring dialysis and in three healthy volunteers after a rapid i.v. infusion of 20mg. Mean plasma concentrations at the end of infusion were 3.15 times higher in patients with CRF than in healthy

Mirtazapine oral single dose kinetics in
Mirtazapine oral single dose kinetics in patients with different degrees of renal failure
✍ F. Bengtsson; P. Höglund; C. Timmer; J. Hegbrant 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 1 views

To investigate pharmacokinetic parameters, as well as safety of mirtazapine in patients with renal failure, an openlabelled, single oral dose study was performed in normal healthy controls and in patients with mild, moderate and severe renal failure, as distinguished by glomerular ®ltration rates (G